Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, HT Zhang, YM Zhang… - OncoTargets and therapy, 2017 - Taylor & Francis
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …
被引用次数：38 相关文章
[HTML] nih.gov

[HTML][HTML] Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, HT Zhang, YM Zhang… - OncoTargets and therapy, 2017 - ncbi.nlm.nih.gov
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

SC Fang, HT Zhang, YM Zhang, WP Xie - Oncotargets and Therapy, 2017 - europepmc.org
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

SC Fang, HT Zhang, YM Zhang… - OncoTargets & …, 2017 - search.ebscohost.com
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, HT Zhang, YM Zhang… - OncoTargets and …, 2017 - pubmed.ncbi.nlm.nih.gov
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, HT Zhang, YM Zhang, WP Xie - OncoTargets and Therapy, 2017 - go.gale.com
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, Z Hai-Tao, Z Ying-Ming… - OncoTargets and …, 2017 - search.proquest.com
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

SC Fang, HT Zhang, YM Zhang… - OncoTargets and Therapy, 2017 - dovepress.com
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

SC Fang, HT Zhang, YM Zhang, WP Xie - Oncotargets and Therapy, 2017 - europepmc.org
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.

SC Fang, HT Zhang, YM Zhang… - OncoTargets & …, 2017 - search.ebscohost.com
In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …